WuXi AppTec expands San Diego R&D site

WuXi AppTec is to expand its facilities in San Diego, by establishing a centre of excellence in screening, discovery biology, pharmacology and small molecule process R&D. This will include Phase I GMP manufacturing. The company said that this will “provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries”. The amount being invested has not been disclosed.

Headquartered in Wuxi, China, WuXi Apptec has expanded across the world in recent years and is particularly active in the US. In all, the company has 27 sites, of which eight are in the US and employ about 1,700 people. It describes itself as a “pharmaceutical and medical device open-access capability and technology platform company”. Its technologies, most notably small molecule drug R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, are used by some 3,000 customers in over 30 countries